Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Shanghai-based Hengrui Pharmaceuticals has obtained FDA’s approval to start Phase I human trials in the U.S. for retagliptin, a compound for treating type 2 diabetes. The company says it is the first China-based company to get a green light for U.S. testing of a small-molecule drug invented in China. Belonging to the same class of compounds as Merck & Co.’s sitagliptin drug, retagliptin is another type of dipeptidyl peptidase-4 inhibitor.
This article has been sent to the following recipient: